original ) (raw )Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup
Anna Oswald
The Journal of rheumatology, 2006
View PDFchevron_right
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial
Joachim Listing
Arthritis & Rheumatism, 2003
View PDFchevron_right
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice
H. Haibel
Clinical and experimental rheumatology, 2008
View PDFchevron_right
Visceral Fat Reflects Disease Activity in Patients with Ankylosing Spondylitis
Mehmet Ata Akıl
Clinical & Investigative Medicine, 2014
View PDFchevron_right
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab
Joachim Listing
Rheumatology, 2007
View PDFchevron_right
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system
Joachim Listing
Arthritis & Rheumatism, 2003
View PDFchevron_right
Treatment of ankylosing spondylitis with infliximab
Wolfgang Kellner
Annals of the Rheumatic Diseases, 2001
View PDFchevron_right
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
Orsolya Balogh
The European journal of health economics : HEPAC : health economics in prevention and care, 2014
View PDFchevron_right
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis
Majed Khraishi
BMJ open, 2016
View PDFchevron_right
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor antibody infliximab
Joachim Listing
Annals of the Rheumatic Diseases, 2005
View PDFchevron_right
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Mariagrazia Lorenzin
BMC Musculoskeletal Disorders
View PDFchevron_right
Disease activity and functional outcomes in non-radiographic spondyloarthritis versus ankylosing spondylitis – preliminary results
Andreea Hortolomei
Romanian Journal of Rheumatology
View PDFchevron_right
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
Jacqueline G
Annals of The Rheumatic Diseases, 2005
View PDFchevron_right
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial
Jehan-michel Béhier
Arthritis & Rheumatism, 2005
View PDFchevron_right
Persistent clinical response to the anti-TNF- antibody infliximab in patients with ankylosing spondylitis over 3 years
Joachim Listing
Rheumatology, 2005
View PDFchevron_right
The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study
Helena D'Elia
Arthritis Research & Therapy, 2015
View PDFchevron_right
High prevalence of metabolic syndrome in patients with ankylosing spondylitis
Vikash Singh
Clinical …, 2007
View PDFchevron_right
Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study
Mats Geijer
Mediators of Inflammation, 2013
View PDFchevron_right
Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies
Thao Pham
Joint, bone, spine : revue du rhumatisme, 2015
View PDFchevron_right
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome
H. Haibel
Rheumatology, 2011
View PDFchevron_right
Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis
James Malley
Arthritis & Rheumatism, 2009
View PDFchevron_right
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Canadian Prospective Observational Registry
Michelle Teo
2020
View PDFchevron_right
Visceral Fat Re ects Disease Activity in Patients with Ankylosing Spondylitis
Mehmet Ata Akıl
2014
View PDFchevron_right
Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years
Nur Riska
Rheumatology, 2005
View PDFchevron_right
Infliximab Therapy for Patients With Active and Refractory Spondyloarthropathies at the Dose of 3 mg/kg
Menelaos N . Manoussakis
JCR: Journal of Clinical Rheumatology, 2004
View PDFchevron_right
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Joachim Listing
Arthritis research & therapy, 2005
View PDFchevron_right
Measuring enthesitis in ankylosing spondylitis
Ismail Bejia
Joint Bone Spine, 2006
View PDFchevron_right
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis
H. Haibel
The Journal of rheumatology, 2007
View PDFchevron_right
Lipid profile in a sample of Iraqi Patients with Ankylosing Spondylitis treated with TNF alpha inhibitor (Infliximab
Mohammed Alosami
View PDFchevron_right
Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment
Eva Klingberg , Helena D'Elia , Jan H Gothlin , Mats Geijer
Arthritis Research & Therapy, 2012
View PDFchevron_right